95 related articles for article (PubMed ID: 7950774)
1. [Directions in the development of postsynaptic nondepolarizing muscle relaxants with rapidly developing action].
Danilov AF; Zhabko EP; Fedorov IuD
Eksp Klin Farmakol; 1994; 57(4):18-20. PubMed ID: 7950774
[TBL] [Abstract][Full Text] [Related]
2. [The inhibition of synaptic acetylcholinesterase by postsynaptic muscle relaxants].
Danilov AF; Malygin VV
Eksp Klin Farmakol; 1997; 60(1):25-7. PubMed ID: 9162276
[TBL] [Abstract][Full Text] [Related]
3. [A nondepolarizing muscle relaxant with rapidly developing and short-term action].
Danilov AF; Zhabko EP
Eksp Klin Farmakol; 1998; 61(5):18-20. PubMed ID: 9854626
[TBL] [Abstract][Full Text] [Related]
4. [The future directions in the search for postsynaptic muscle relaxants with rapidly developing and short-term action].
Danilov AF
Eksp Klin Farmakol; 1993; 56(4):3-6. PubMed ID: 8220010
[No Abstract] [Full Text] [Related]
5. [Role of the hydrophobicity of monoquaternary ammonium compounds in the mechanism of their curariform action].
Drozhzhin AP; Ibadova DN
Farmakol Toksikol; 1975; 38(3):289-94. PubMed ID: 132360
[TBL] [Abstract][Full Text] [Related]
6. [Decurarization using the cation-anion molecular interaction of a myorelaxant and its antagonist].
Grechishkin LL; Krasnova EI; Indenbom ML
Farmakol Toksikol; 1979; 42(4):362-5. PubMed ID: 157883
[TBL] [Abstract][Full Text] [Related]
7. In search of new neuromuscular blocking drugs with quick onset and short duration of effect.
Danilov AF; Gmiro VE; Fedorov DJ
Eur J Pharmacol; 1994 May; 257(1-2):1-5. PubMed ID: 8082688
[TBL] [Abstract][Full Text] [Related]
8. [Postsynaptic nondepolarizing muscle relaxants in clinical practice].
Danilov AF
Eksp Klin Farmakol; 1998; 61(3):74-80. PubMed ID: 9690085
[TBL] [Abstract][Full Text] [Related]
9. [Clinical differentiation of the modes of action of muscle relaxants].
Mori K; Yamamura Y; Fujita M
Masui; 1971 Nov; 20(12):1087-94. PubMed ID: 4260219
[No Abstract] [Full Text] [Related]
10. [Relationship between the effect of proserine on the action of myorelaxants and their proper anticholinesterase activity].
Danilov AF
Eksp Khir Anesteziol; 1969; 14(1):59-64. PubMed ID: 4244999
[No Abstract] [Full Text] [Related]
11. Proceedings: Quantitative clinical studies on the action and on the duration of action of nondepolarizing muscle relaxants.
Schuh FT
Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R97. PubMed ID: 124822
[No Abstract] [Full Text] [Related]
12. [Myorelaxants in pediatric anesthesia].
Curreri G; Ancona MA; Sciascia M
Minerva Anestesiol; 1996 Apr; 62(4):125-30. PubMed ID: 8984425
[TBL] [Abstract][Full Text] [Related]
13. Muscle relaxants: a clinical update.
Buzello W; Diefenbach C; Nigrovic V
Acta Anaesthesiol Scand Suppl; 1996; 109():165-7. PubMed ID: 8901994
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle relaxants: pharmacodynamics and pharmacokinetics in different patient groups.
Booij LH; Vree TB
Int J Clin Pract; 2000 Oct; 54(8):526-34. PubMed ID: 11198732
[TBL] [Abstract][Full Text] [Related]
15. Mivacurium.
Feldman S
Br J Hosp Med; 1997 Mar 5-18; 57(5):199-201. PubMed ID: 9176596
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous muscle action potentials are blocked by N-type and P/Q-calcium channels blockers in the rat spinal cord-muscle co-culture system.
Taguchi K; Shiina M; Shibata K; Utsunomiya I; Miyatake T
Brain Res; 2005 Feb; 1034(1-2):62-70. PubMed ID: 15713260
[TBL] [Abstract][Full Text] [Related]
17. [Clinical administration of muscle relaxants for intubation].
Hofmockel R; Pohl B; Nöldge-Schomburg G
Anaesthesiol Reanim; 2001; 26(5):116-22. PubMed ID: 11712228
[TBL] [Abstract][Full Text] [Related]
18. [The presynaptic action of muscle relaxants and cholinesterase inhibitors].
Danilov AF
Eksp Klin Farmakol; 1997; 60(4):83-7. PubMed ID: 9376769
[TBL] [Abstract][Full Text] [Related]
19. Role for the skeletal muscle action potential in non-Hebbian long-term depression at the amphibian (Bufo marinus) neuromuscular junction.
Etherington SJ; Everett AW
Synapse; 2008 Apr; 62(4):291-301. PubMed ID: 18240324
[TBL] [Abstract][Full Text] [Related]
20. Rocuronium 0.3 mg x kg-1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy.
Muenster T; Schmidt J; Wick S; Forst J; Schmitt HJ
Paediatr Anaesth; 2006 Aug; 16(8):840-5. PubMed ID: 16884467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
